📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. (2022)

First Author: Pepper AGS

Attributed to: Overcoming Ibrutinib and Venetoclax resistance in Chronic Lymphocytic Leukaemia. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41375-021-01322-1

PubMed Identifier: 34148055

Publication URI: http://europepmc.org/abstract/MED/34148055

Type: Journal Article/Review

Volume: 36

Parent Publication: Leukemia

Issue: 1

ISSN: 0887-6924